Effects of Reslizumab on Nasal Polyp Inflammation in Aspirin Exacerbated Respiratory Disease

Effects of Reslizumab on Nasal Polyp Inflammation in Aspirin Exacerbated Respiratory Disease

Gene expression, protein levels, and cellular infiltrates were assessed using RT-PCR, ELISA, flow cytometry, and immunohistochemistry. NP ECP protein levels and CCR3 and CLC gene expression levels were reduced by 90-fold, 25-fold, and 300-fold respectively post-Reslizumab compared to pre-Reslizumab.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB408-AB408
Hauptverfasser: Stevens, Whitney W., Staudacher, Anna G., Peters, Anju T., Suh, Lydia A., Carter, Roderick G., Fischer, Stephanie R., Hulse, Kathryn E., Poposki, Julie A., Norton, James E., Kato, Atsushi, Grammer, Leslie C., Conley, David B., Kern, Robert C., Shintani-Smith, Stephanie, Tan, Bruce K., Welch, Kevin C., Schleimer, Robert P.
Format: Artikel
Sprache:eng
Schlagworte:
Aspirin
Gene expression
Monoclonal antibodies
Respiratory diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Gene expression, protein levels, and cellular infiltrates were assessed using RT-PCR, ELISA, flow cytometry, and immunohistochemistry. NP ECP protein levels and CCR3 and CLC gene expression levels were reduced by 90-fold, 25-fold, and 300-fold respectively post-Reslizumab compared to pre-Reslizumab.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.963